title: Long-term outcome after pancreas transplantation.
abstract: OBJECTIVE
  Pancreas transplantation provides the only proven method to restore long-term normoglycemia in patients with insulin-dependent diabetes mellitus. Although many studies describe the very important risk factors for short-term survival of a pancreas transplant, there is not a lot of information available about factors that distinguish short-term from long-term graft function.
  
  
  RESULTS
  The analysis of 18,159 pancreas transplants from the International Pancreas Transplant Registry, performed from 25 July 1978 to 31 December 2005, showed an improvement not only in short-term but also in long-term graft function. Most recent 5-year, 10-year and 20-year graft function for transplants with the appropriate follow-up time showed 80, 68 and 45%, respectively, for simultaneous pancreas/kidney transplants; 62, 46 and 16%, respectively, for pancreas after kidney; and 59, 39 and 12%, respectively, for pancreas transplants alone. Important factors influencing long-term function were factors that described the quality of the deceased donor. Pancreas transplants in younger or African-American recipients showed a higher risk of graft failure. Anti-T-cell induction therapy had a significant impact on long-term survival in solitary transplants.
  
  
  CONCLUSIONS
  With a careful donor selection, not only short-term but also long-term pancreas graft function and, therefore, good metabolic control can be achieved for the diabetic patient.
authors.affiliation: College of Public Health, University of Arizona, 1295 N. Martin Ave, Tucson, AZ 85724-5163, USA. acgruess@email.arizona.edu
authors.forename: Angelika C
authors.initials: AC
authors.lastname: Gruessner
authors.forename: David E R
authors.initials: DE
authors.lastname: Sutherland
authors.forename: Rainer W G
authors.initials: RW
authors.lastname: Gruessner
mesh_terms: D003657:Decision Making; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000150:complications; D006085:Graft Survival; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D000078790:Insulin Secretion; D016030:Kidney Transplantation; D019520:Living Donors; D016015:Logistic Models; D016035:Pancreas Transplantation; D006435:Renal Dialysis / Q000009:adverse effects; D051437:Renal Insufficiency / Q000209:etiology / Q000601:surgery* / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome; D014850:Waiting Lists
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin